Superworth

Tempest Therapeutics EPS TPST

Diluted earnings per share by quarter and over the last twelve months, from 2011.

Last 12 months, to Jun 30, 2026
−$4.48
Latest quarter, Q2 FY26
−$0.34
Fiscal year 2025
−$6.84

Tempest Therapeutics' earnings per share was −$4.48 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.34.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$6.84n/a
FY2024−$19.85n/a
FY2023−$25.48n/a
FY2022−$42.77n/a
FY2021−$266.76n/a
FY2020−$497.12n/a
FY2019−$635.70n/a
FY2018−$5079.75n/a
FY2017−$4182.75n/a
FY2016−$7605.00n/a
FY2015−$7926.75n/a
FY2014−$6318.00n/a
FY2013−$5235.75n/a
FY2012−$14566.50n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$0.34n/a−$4.48
Q1 FY26−$2.53n/a−$6.21
Q4 FY25−$0.82n/a−$6.84
Q3 FY25−$0.79n/a−$10.41
Q2 FY25−$2.07n/a−$14.94
Q1 FY25−$3.16n/a−$18.39
Q4 FY24−$4.39n/a−$19.85
Q3 FY24−$5.32n/a−$20.53
Q2 FY24−$5.52n/a−$21.45
Q1 FY24−$4.62n/a−$22.95
Q4 FY23−$5.07n/a−$25.48
Q3 FY23−$6.24n/a−$28.99

Against its peers

Companies in Drug Manufacturers - General nearest Tempest Therapeutics' size, closest first, today.

CompanyEPS, 12 monthsGrowth
TPSTTempest Therapeutics−$4.48
ATNMActinium Pharmaceuticals$0.36
SPROSpero Therapeutics$0.11
LFVNLifevantage$0.40−46% a year
Peer median$0.36

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Tempest Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.